Juvenescence is one of the more recent venture groups to become enthusiastically involved in supporting the development of means to treat aging, and the organization’s principals are now beginning to build their positions in earnest. As this unfolds, we obtain insight into their interpretation of the field of longevity science, the lines of development that they believe to be plausible and interesting. The founding members have expressed a strong interest in SENS rejuvenation research programs, but will they follow up with the investments to match? It always seems impolite to ask that question, but our community has been disappointed in the past.
You might recall that Juvenescence invested in AgeX Therapeutics not so long ago. AgeX aims to build out an platform that is intended as an incremental advance over present approaches to regenerative medicine, mixing in telomerase upregulation with the production and deployment of cell therapies. Juvenescence has now expanded their support of AgeX Therapeutics. It will be interesting to see how this line of work matures, and whether the AgeX staff choose to explore some of the surprising outcomes that are emerging from the induced pluripotency field these days, particularly
Article originally posted at